Sells branded and compounded prescription medicines for eye conditions to eyecare professionals, pharmacies, and patients.
10-K for FY2025, filed Mar 2, 2026We are a leading provider of ophthalmic disease management solutions in North America, and were founded with a commitment to deliver safe…View ↗
Branded Ophthalmic PharmaceuticalsView ↗
ImprimisRx is our ophthalmology-focused pharmaceutical compounding business. Since inception in 2014, ImprimisRx has provided…View ↗
Customers buy prescription medicines through Harrow’s pharmacy, outsourcing facility and distribution partner; Harrow earns product revenue when goods ship, or on delivery under some contracts. It also earns revenue from intellectual-property licenses.
10-K for FY2025, filed Mar 2, 2026The Company accounts for contracts with customers in accordance with ASC 606, Revenues from Contracts with Customers. The Company has two…View ↗
The Company sells prescription medications directly through its pharmacy, outsourcing facility and 3PL partner. Revenue from the Company’s…View ↗
Identify the contract(s) with a customer: A contract is deemed to exist when the customer places an order through receipt of a…View ↗
Recognize revenue when (or as) the entity satisfies a performance obligation: Revenue from products is recognized upon transfer of control…View ↗
10-K for FY2025, filed Mar 2, 2026
FY2025 revenue by product or service ↗$272.3M
10-K for FY2025, filed Mar 2, 2026
$272.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product Sales Net
Sold outright
10-K for FY2025, filed Mar 2, 2026 |
100%
FY2022: 94%
|
Product Sales Net, FY2025
$271.9M Sources
|
Sold outright |
|
Other Revenues
|
0.1%
FY2022: 5.7%
|
Other Revenues, FY2025
$394K Sources
|
Branded medicines generally go through third-party distributors to pharmacies and end users; compounded medicines are dispensed through Harrow’s pharmacy for patients or prepared for in-office use.
10-K for FY2025, filed Mar 2, 2026
Not on paper. It lost $5.1M in FY2025, but brought in more cash than it spent: $43M of free cash flow.
10-Q for Q3 FY2026, filed Nov 9, 2026
Open tableView ↗
8-K, filed Nov 9, 2026
Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year Branded revenue of $83.5 million, up 62% year…View ↗
8-K, filed Oct 5, 2026
At the Closing, the Company paid Viatris $30.0 million in cash, funded with cash on hand. Pursuant to the Purchase Agreement, the Company…View ↗
Growing. Revenue grew 3.8x in 4 years, from $72.5M in FY2021 to $272.3M in FY2025, about 39% a year.
Melt ownership
Harrow moved from holding a minority stake and royalty rights in Melt to owning Melt’s drug candidates and including its research and development in consolidated results.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 2, 2026We are an ophthalmic-focused pharmaceutical company. Our business specializes in the development, production, sale, and distribution of…View ↗
Loading...